BioCentury
ARTICLE | Company News

Infinity scores $130M milestone from AbbVie

October 1, 2015 1:02 AM UTC

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) gained $0.52 to $8.45 on Wednesday on news it received a $130 million milestone from AbbVie Inc. (NYSE:ABBV) for completing patient enrollment in the Phase II DYNAMO study of duvelisib ( IPI-145) to treat indolent non-Hodgkin's lymphoma (NHL).

DYNAMO will measure overall response rate (ORR) in 120 patients with refractory disease following treatment with rituximab and either chemotherapy or radioimmunotherapy. Infinity expects topline data in 3Q16. ...